Ikena Oncology, a targeted oncology company forging new territory in patient-directed cancer treatment, agreed to acquire Pionyr Immunotherapeutics, a privately-held, clinical-stage biotechnology company. Financial terms were not disclosed. "Ikena has made incredible strides this year, and we are glad to welcome the Pionyr shareholders to the Ikena team as we head into a pivotal time for our targeted oncology programs. The capital from this acquisition allows us to accelerate and expand our clinical efforts in IK-930 and further support our comprehensive clinical plan for IK-595 as we continue to build value through both depth and breadth in our pipeline. We are looking forward to sharing more updates from across our business and pipeline, including initial clinical data from IK-930 later this year," Mark Manfredi, Ikena CEO.